Key facts
- This page summarizes Reshma Rangwala's Form 4 filing for Aravive, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Jan 2022, 15:05.
Reshma Rangwala - 24 Jan 2022 Form 4 Insider Report for Aravive, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 24 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2022, 15:05:28 UTC
- Next SEC filing
- 29 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Abel Svitavsky, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Reshma Rangwala filed Form 4 for Aravive, Inc. on 25 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARAV
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- Price
- $0.000000
- Shares after
- 175,000
- Date
- 24 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 175,000
- Exercise price
- $2.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date.